Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
It’s just a mouse study, but intriguing all the same: Lithium may show promise as an Alzheimer’s treatment. Also, Eli Lilly’s oral weight loss pill falls short of GLP-1 stalwarts, and more.
The need-to-know this morning
- Strand Therapeutics, a privately held developer of cancer drugs, raised $153 million in a Series B round of financing. The company intends to use the money to advance the development of an mRNA-based drug currently in early stage studies for the treatment of solid tumors.
Eli Lilly’s key obesity pill falls short of rivals
Eli Lilly said this morning that its experimental obesity pill orforglipron fell short of expectations in a late-stage trial, delivering 11.2% weight loss over 72 weeks — less than the 15% to 21% reductions seen with injectables like Wegovy and Zepbound.
